Company profile
Protalix BioTherapeutics, Inc.
AMEX:PLXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Pegunigalsidase Alfa | phase3 | — | 5 | completed, withdrawn |
| TALIGLUCERASE ALFA | phase2 | — | 8 | completed, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (16)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05745727 | phase1 | completed | 2023-03-23 | 2024-08-26 | Protalix | A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels |
| NCT07280156 | phase2 | recruiting | 2025-12-22 | 2027-12-01 | Protalix | A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE) |
| NCT01093859 | — | completed | 2010-03-01 | 2010-05-01 | Protalix | An Exploratory Phase 1 Microdose Study of PRX-105 |
| NCT02107846 | phase2 | completed | 2014-04-01 | 2015-12-01 | Protalix | An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 |
| NCT01678898 | phase1_2 | completed | 2012-10-01 | 2016-03-06 | Protalix | Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients |
FDA applications (0)
No records yet.